These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 37996010

  • 1. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
    Kubota-Ishida N, Kaji C, Matsumoto S, Wakabayashi T, Matsuhira T, Okura I, Cho N, Isshiki S, Kumura K, Tabata Y.
    Eur J Pharmacol; 2024 Jan 05; 962():176202. PubMed ID: 37996010
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
    Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, Jones-Iatauro S, Sexton H, Martin S, Dee J, Mak Y, Meewan M, Rock F, Akama T, Jarnagin K.
    J Pharmacol Exp Ther; 2016 Sep 05; 358(3):413-22. PubMed ID: 27353073
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
    Kubota-Ishida N, Matsuhira T, Kaji C, Kikuchi C, Tabata Y.
    Eur J Pharmacol; 2021 Sep 05; 906():174258. PubMed ID: 34139195
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases].
    Schmidt MF, Albuscheit N, Yazdi AS.
    Dermatologie (Heidelb); 2024 Oct 05; 75(10):791-797. PubMed ID: 39212723
    [Abstract] [Full Text] [Related]

  • 12. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.
    Cell Signal; 2014 Sep 05; 26(9):2016-29. PubMed ID: 24882690
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M, Papp K.
    BioDrugs; 2015 Oct 05; 29(5):327-39. PubMed ID: 26481941
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, Lebwohl MG.
    J Drugs Dermatol; 2016 Apr 05; 15(4):390-6. PubMed ID: 27050693
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
    Asaka N, Kakuo H, Ohmori K, Sasaki E, Togawa M, Yamada S, Oka T, Kiniwa M.
    Arzneimittelforschung; 2010 Apr 05; 60(9):564-70. PubMed ID: 21117500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.